Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
1. Cocrystal's CDI-988 aims to treat norovirus infections. 2. FDA approved a Phase 1b study for CDI-988's clinical trials. 3. Norovirus is a major public health issue in the U.S. 4. CDI-988 shows broad-spectrum antiviral activity against norovirus. 5. The Phase 1b study is expected to begin by year-end 2025.